tion, associated with disturbed intracellular Ca homeofailure. However, several clinical trials revealed that even stasis. Under physiological conditions, cardiac contraction though the hemodynamic symptoms were improved shortly 21 is initiated by Ca influx through sarcolemmal L-type after administration of b-adrenergic receptor agonists, 21 Ca channels, which subsequently triggers a large amount chronic administration increased mortality in treated pa-21 of Ca release from the internal sarcoplasmic reticulum tients [7, 8] . Similarly, other attempts aimed at improving (SR) stores via ryanodine receptors. The increased intracelcontractile function by raising intracellular cAMP level 21 lular Ca activates the contractile myofilaments, and then using cyclic nucleotide phosphodiesterase (PDE) inhibitors 21 is either recycled back into the SR by SR Ca pumps or results in increased mortality during chronic administration 1 21 extruded out of the cell via sarcolemmal Na -Ca in heart failure patients [9] [10] [11] . Furthermore, transgenic exchanger, resulting in cardiac muscle relaxation. Profound mice overexpressing b -adrenergic receptors [12] [3] [4] [5] . Restoration of these Ca handling deficits is activation of b-adrenergic receptor / cAMP system may expected to have beneficial effects in patients with heart provide a short-term hemodynamic improvement, but failure.
damages the failing heart in the long run. Thus, the The intracellular second messenger, cyclic adenosine reduced cardiac contractile response to b-adrenergic remonophosphate (cAMP), activates cAMP-dependent proceptor stimulation (attributed to selective downregulation tein kinase A, which subsequently phosphorylates many of of b1-adrenergic receptors, upregulation of b-ARK1 and the cardiac excitation-contraction components (including an increase in G proteins) might be considered to be a i 21
1 21
L-type Ca channel, ryanodine receptor, Na -Ca beneficial compensatory effect to the high plasma catecholexchanger, myofilament proteins and phospholamban).
amine levels observed in patients with heart failure [14] . How can we reconcile these apparently disparate lines of are presumably activated non-selectively by NDPK. In evidence? One emerging possibility is that the same canine cardiac sarcolemmal membranes, activation of second messenger, cAMP, may produce different func-NDPK stimulates adenylyl cyclase and increases cAMP tional consequence depending on how cAMP is generated. levels [35] , whereas in normal human cardiac sarcolemmal It has been well known that cAMP from different sources membrane, inhibition of NDPK has no effect on adenylyl might exist in different intracellular compartments. For cyclase activity [33] . The important finding by Niroomand example, both b -and b -adrenergic receptor stimulation and his colleagues [33] is that both the protein level and 1 2 increase total cellular cAMP levels to a similar extent in the activity of NDPK are significantly increased in human rat cardiac myocytes, but the augmentation of cAMP in the failing hearts as compared to non-failing controls. Interestparticulate fraction is higher for b -adrenergic receptor ingly, these changes are limited to the sarcolemmal phorylates both sarcolemmal (Ca channel) and cytotivities are similar between the two groups, stimulation of plasmic proteins (phospholamban, glycogen phosphorylase adenylyl cyclase activity by physiological concentrations kinase, troponin I and C), activation of b -adrenergic of GDP and ATP is greater in control hearts than in failing 2 21 receptor only modulates sarcolemmal Ca channel withhearts. The authors contend that this difference is mainly out phosphorylation of non-sarcolemmal proteins [24] . due to the greater inhibitory effect of NDPK on adenylyl Functionally, b -adrenergic stimulation in rat cardiac cyclase activity in failing hearts. These results provide the 1 myocytes elicits not only positive inotropic effects, but first evidence that sarcolemmal membrane-associated 21 also enhanced lusitropy and spontaneous Ca oscillations. NDPK is up regulated during heart failure and may serve In contrast, the latter effects are absent during b -adrenas a novel mechanism contributing to the diminished 2 ergic stimulation [25] . More surprisingly, b -and bcAMP signaling observed in the failing heart. . Therefore, spatially development of cardiac dysfunction, but in addition repredistinct cAMP signals generated by different b-adrenergic sent key molecular targets for the treatment of failing receptor subtypes provide a mechanism by which a single heart. As discussed above, the lack of efficient prevention second messenger can produce diverse final outcomes.
and treatment of heart failure is partially due to the Emerging evidence also suggests that spatially localized complicated roles of cAMP from different sources or cAMP signaling can be achieved by various active receptor compartments. The discovery of NDPK as a new member states [27, 28] , different anchoring proteins [29, 30] and in cAMP signaling cascade might provide another piece of various isoforms of protein kinases [30] or phosphatases information to help solve this puzzle. Meanwhile, this [31] . For the treatment of heart failure, it might be intriguing result also raises many interesting aspects for important to choose the cAMP-generating mechanisms that future studies: What is the mechanism(s) for the alteration selectively enhance beneficial effects such as contractile of sarcolemmal membrane-associated NDPK in heart metoprolol in idiopathic dilated cardiomyopathy. 
